Commentary: The Injustice of Paediatric Drug Labelling in Canada - A Call to Action.

Abstract

Building upon the article by Moore Hepburn et al. (2023), this rejoinder acts to reinforce the inadequacy of current drug labelling laws and the urgency of the need for improved paediatric drug regulation in Canada. To facilitate a path forward, specific examples of success in other trusted foreign jurisdictions are provided. A call to educate parents and the public about the current lack of paediatric drug labelling and the ways that multi-stakeholder groups can work together to ensure safe and effective pharmacotherapy for Canadian children are highlighted.